As in the case of the other S1PR modulators, the main mechanism of action of siponimod in MS, as well as the most common side effects, are related to its effects on S1PR1 [42] (see section 8 and Tables 2 and 3 for side effects and practical recommendations for risk mitigation). The gene discussed is S1PR1; the disease is myeloid sarcoma.